- Home
- FFA vs AKBA Comparison
FFA vs AKBA Comparison
Compare FFA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 375.0M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FFA | AKBA |
|---|---|---|
| Price | $22.33 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 22.4K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.21 | $1.13 |
| 52 Week High | $22.54 | $4.08 |
Technical Indicators
Market Signals| Indicator | FFA | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | 36.48 |
| Support Level | $21.67 | $1.16 |
| Resistance Level | N/A | $1.56 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 70.83 | 14.46 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.